Alok A. Khorana, MD

Articles by Alok A. Khorana, MD

Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer

BySuneel D. Kamath, MD,Joanna Roopkumar, MD,Ying Ni, PhD,Minqian Shen, MD, PhD,Pablo Bejarano, MD,Daniela Allende, MD,Arun Nagarajan, MD,Tim Nguyen, MD,Bachar Dergham, MD,Dale Shepard, MD, PhD,Marc A. Shapiro, MD,Michael J. McNamara, MD,Bassam N. Estfan, MD,Kanika G. Nair, MD,Alok A. Khorana, MD

December 15th 2023

Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.

Shorter Time to Treatment Is Associated With Improved Survival in Rural Patients With Breast Cancer Despite Other Adverse Socioeconomic Factors

ByMinhTri Nguyen, MD,Wei Wei, MS,Gregory Cooper, MD,Alok A. Khorana, MD,Suneel D. Kamath, MD

January 28th 2023

Minh-Tri Nguyen, MD, and colleagues investigate the association between time to treatment, socioeconomic status, and clinical outcomes among rural and urban patients with breast cancer.

Latest Updated Articles

Trending on CancerNetwork

122 Adjuvant Ribociclib (RIB) Plus Nonsteroidal Aromatase Inhibitor (NSAI) in Patients With HR+/HER2− Early Breast Cancer (EBC): NATALEE 5-Year Outcomes

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

121 Five-Year Analysis of Distant Disease-Free Survival (DDFS) Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib (RIB) Plus a Nonsteroidal Aromatase Inhibitor (NSAI) in Patients With HR+/HER2− Early Breast Cancer (EBC)